HIV patients may ditch daily pills for monthly shots

NCT ID NCT02938520

Ongoing Disease control Sponsor: ViiV Healthcare Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This Phase 3 trial tests whether people with HIV who are already well-controlled on daily pills can switch to a monthly injection of two drugs (cabotegravir and rilpivirine) and stay just as healthy. About 630 adults whose virus is suppressed on a standard three-drug pill regimen will either continue their daily pills or switch to the monthly shots. The goal is to see if the injections are as good at keeping the virus undetectable over 48 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cabotegravir and rilpivirine (injectable long-acting formulation)
What this could lead to: If successful, this could offer people with HIV a convenient monthly injection instead of daily pills, making it easier to stay on treatment and maintain viral suppression.
What could go wrong: This is a Phase 3 trial, but the injections may cause injection-site reactions or fail to suppress the virus in some people. Long-term safety and effectiveness beyond 48 weeks are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

GSK Investigational Site

Birmingham, Alabama, 35294, United States
GSK Investigational Site

Bakersfield, California, 93301, United States
GSK Investigational Site

Long Beach, California, 90813, United States
GSK Investigational Site

Los Angeles, California, 90019, United States
GSK Investigational Site

Los Angeles, California, 90027, United States
GSK Investigational Site

San Francisco, California, 94109, United States
GSK Investigational Site

Aurora, Colorado, 80045, United States
GSK Investigational Site

Washington D.C., District of Columbia, 20005, United States
GSK Investigational Site

Fort Lauderdale, Florida, 33316, United States
GSK Investigational Site

Orlando, Florida, 32806, United States
GSK Investigational Site

Atlanta, Georgia, 30312, United States
GSK Investigational Site

Augusta, Georgia, 30912-3130, United States
GSK Investigational Site

Macon, Georgia, 31201, United States
GSK Investigational Site

Indianapolis, Indiana, 46202, United States
GSK Investigational Site

Minneapolis, Minnesota, 55415, United States
GSK Investigational Site

Omaha, Nebraska, 68198, United States
GSK Investigational Site

Camden, New Jersey, 08103, United States
GSK Investigational Site

New York, New York, 10029, United States
GSK Investigational Site

Providence, Rhode Island, 02904, United States
GSK Investigational Site

Austin, Texas, 78705, United States
GSK Investigational Site

Bellaire, Texas, 77401, United States
GSK Investigational Site

Dallas, Texas, 75246, United States
GSK Investigational Site

Fort Worth, Texas, 76104, United States
GSK Investigational Site

Longview, Texas, 75605, United States
GSK Investigational Site

Lynchburg, Virginia, 24501, United States
GSK Investigational Site

Vancouver, British Columbia, V6Z 2C7, Canada
GSK Investigational Site

Ottawa, Ontario, K1H 8L6, Canada
GSK Investigational Site

Toronto, Ontario, M5B 1W8, Canada
GSK Investigational Site

Toronto, Ontario, M5G 1K2, Canada
GSK Investigational Site

Toronto, Ontario, M5G 2N2, Canada
GSK Investigational Site

Montreal, Quebec, H2L 4P9, Canada
GSK Investigational Site

Bobigny, 93009, France
GSK Investigational Site

Lyon, 69437, France
GSK Investigational Site

Marseille, 13003, France
GSK Investigational Site

Paris, 75018, France
GSK Investigational Site

Paris, 75475, France
GSK Investigational Site

Paris, 75571, France
GSK Investigational Site

Paris, 75651, France
GSK Investigational Site

Paris, 75970, France
GSK Investigational Site

Berlin, 10439, Germany
GSK Investigational Site

Berlin, 10787, Germany
GSK Investigational Site

Bonn, 53127, Germany
GSK Investigational Site

Essen, 45122, Germany
GSK Investigational Site

Frankfurt, 60590, Germany
GSK Investigational Site

Frankfurt, 60596, Germany
GSK Investigational Site

Hamburg, 20146, Germany
GSK Investigational Site

Hamburg, 20246, Germany
GSK Investigational Site

Hanover, 30625, Germany
GSK Investigational Site

München, 80336, Germany
GSK Investigational Site

München, 80337, Germany
GSK Investigational Site

Brescia, 25123, Italy
GSK Investigational Site

Milan, 20127, Italy
GSK Investigational Site

Milan, 20157, Italy
GSK Investigational Site

Monza MB, 20900, Italy
GSK Investigational Site

Roma, 00149, Italy
GSK Investigational Site

Aichi, 460-0001, Japan
GSK Investigational Site

Osaka, 540-0006, Japan
GSK Investigational Site

Tokyo, 162-8655, Japan
GSK Investigational Site

Amsterdam, 1105 AZ, Netherlands
GSK Investigational Site

Groningen, 9713 GZ, Netherlands
GSK Investigational Site

Rotterdam, 3079 DZ, Netherlands
GSK Investigational Site

Utrecht, 3584 CX, Netherlands
GSK Investigational Site

Kazan', 420061, Russia
GSK Investigational Site

Kemerovo, 650056, Russia
GSK Investigational Site

Krasnodar, 350015, Russia
GSK Investigational Site

Lipetsk, 398043, Russia
GSK Investigational Site

Moscow, 115035, Russia
GSK Investigational Site

Oryol, 302040, Russia
GSK Investigational Site

Saint Petersburg, 190020, Russia
GSK Investigational Site

Saint Petersburg, 193167, Russia
GSK Investigational Site

Saint Petersburg, 196645, Russia
GSK Investigational Site

Saratov, 410009, Russia
GSK Investigational Site

Smolensk, 214006, Russia
GSK Investigational Site

Toliyatti, 445846, Russia
GSK Investigational Site

Yekaterinburg, 620102, Russia
GSK Investigational Site

Bloemfontein, 9301, South Africa
GSK Investigational Site

Cape Town, 7925, South Africa
GSK Investigational Site

Durban, 4052, South Africa
GSK Investigational Site

Durban, 4091, South Africa
GSK Investigational Site

Johannesburg, 2113, South Africa
GSK Investigational Site

Middelburg, 1055, South Africa
GSK Investigational Site

Pretoria, 0087, South Africa
GSK Investigational Site

Winnie Mandela, 9400, South Africa
GSK Investigational Site

A Coruña, 15006, Spain
GSK Investigational Site

Barcelona, 08025, Spain
GSK Investigational Site

Barcelona, 08907, Spain
GSK Investigational Site

Bilbao, 48013, Spain
GSK Investigational Site

Elche Alicante, 03203, Spain
GSK Investigational Site

Ferrol, 15405, Spain
GSK Investigational Site

Granada, 18016, Spain
GSK Investigational Site

La Laguna Santa Cruz, 38320, Spain
GSK Investigational Site

Madrid, 28040, Spain
GSK Investigational Site

Madrid, 28041, Spain
GSK Investigational Site

Madrid, 28046, Spain
GSK Investigational Site

Murcia, 30003, Spain
GSK Investigational Site

Murcia, 30120, Spain
GSK Investigational Site

Palma de Mallorca, 07010, Spain
GSK Investigational Site

Palma de Mallorca, 07198, Spain
GSK Investigational Site

San SebastiAn de Los Rey, 28702, Spain
GSK Investigational Site

Santa Cruz de Tenerife, 38010, Spain
GSK Investigational Site

Santander, 39008, Spain
GSK Investigational Site

Birmingham, B9 5SS, United Kingdom
GSK Investigational Site

Coventry, CV1 4FS, United Kingdom
GSK Investigational Site

Leeds Yorkshire, LS1 3EX, United Kingdom
GSK Investigational Site

London, E1 1BB, United Kingdom
GSK Investigational Site

London, NW3 2QG, United Kingdom
GSK Investigational Site

London, W2 1NY, United Kingdom
GSK Investigational Site

London, WC1E 6JB, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.